[go: up one dir, main page]

NO327709B1 - 2'-substituted 1,1'-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them - Google Patents

2'-substituted 1,1'-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them Download PDF

Info

Publication number
NO327709B1
NO327709B1 NO20021398A NO20021398A NO327709B1 NO 327709 B1 NO327709 B1 NO 327709B1 NO 20021398 A NO20021398 A NO 20021398A NO 20021398 A NO20021398 A NO 20021398A NO 327709 B1 NO327709 B1 NO 327709B1
Authority
NO
Norway
Prior art keywords
atoms
alkyl
phenyl
alkoxy
hydrogen
Prior art date
Application number
NO20021398A
Other languages
Norwegian (no)
Other versions
NO20021398D0 (en
NO20021398L (en
Inventor
Peter Below
Joachim Brendel
Wolfgang Schmidt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20021398D0 publication Critical patent/NO20021398D0/en
Publication of NO20021398L publication Critical patent/NO20021398L/en
Publication of NO327709B1 publication Critical patent/NO327709B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47Y being a hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/16Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04Derivatives of thiourea
    • C07C335/16Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Claims (18)

1. Forbindelser av formel I, hvor R(l) betyr C(0)OR(9), SO2R(10), COR(l 1), C(0)NR(12)R(13) eller C(S)NR(12)R(13); R(9) betyr CxH2x-R(14); x betyr 0,1,2, 3 eller 4, hvor x ikke kan være 0, når R(14) betyr OR(15) eller S02Me; R(14) betyr alkyl med 1,2, 3,4,5 eller 6 C-atomer, cykloalkyl med 3,4, 5,6,7,8,9,10 eller 11 C-atomer, CF3, C2F5, C3F7, CH2F, CHF2, OR(15), S02Me, fenyl, naftyl, bifenylyl, furyl, tienyl eller et N-holdig heteroaromat med 1,2, 3,4, 5,6, 7, 8 eller 9 C-atomer, hvor fenyl, naftyl, bifenylyl, furyl, tienyl og det N-holdige heteroaromat er usubstituert eller substituert med 1, 2 eller 3 substituenter valgt blant gruppen bestående av F, Cl, Br, I, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(15) betyr alkyl med 1,2,3,4 eller 5 C-atomer, cykloalkyl med 3,4, 5 eller 6 C-atomer, CF3 eller fenyl, som er usubstituert eller substituert med 1,2 eller 3 substituenter valgt blant gruppen bestående av F, Cl, Br, I, CF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1, 2, 3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(10),R(ll)ogR(12) er uavhengig av hverandre definert som R(9); R(13) betyr hydrogen, alkyl med 1, 2, 3, eller 4 C-atomer eller CF3; R(2) betyr hydrogen, alkyl med 1,2,3 eller 4 C-atomer eller CF3; R(3) betyr CyH2y-R(16); y betyr 0,1,2,3 eller 4, hvor y ikke kan være 0, når R(16) betyr OR(17) eller S02Me; R(16) betyr alkyl med 1,2, 3,4, 5 eller 6 C-atomer, cykloalkyl med 3,4, 5,6,7, 8,9,10 eller 11 C-atomer, CF3, C2F5, C3F7, CH2F, CHF2, OR(17), S02Me, fenyl, naftyl, furyl, tienyl eller en N-holdig heteroaromat med 1, 2,3,4,5,6, 7,8 eller 9 C-atomer, hvor fenyl, naftyl, furyl, tienyl og det N-holdige heteroaromatet er usubstituert eller substituert med 1,2 eller 3 substituenter valgt blant gruppen bestående av F, Cl, Br, I, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2, 3 eller 4 C-atomer, alkoksy med 1,2,3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(17) betyr hydrogen, alkyl med 1,2, 3,4 eller 5 C-atomer, cykloalkyl med 3,4, 5 eller 6 C-atomer, CF3, fenyl eller 2-, 3- eller 4-pyridyl, hvor fenyl eller 2-, 3- eller 4-pyridyl er usubstituert eller substituert med 1,2 eller 3 substituenter valgt fra gruppen bestående av F, Cl, Br, I, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1, 2, 3 eller 4 C-atomer, alkoksy med 1,2,3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; eller R(3) betyr CHR(18)R(19); R(18) betyr hydrogen eller CzH2z-R(16), hvor R(16) er definert som angitt over; z betyr 0,1,2 eller 3; R(19) betyr COOH, CONH2, CONR(20)R(21), COOR(22), CH2OH; R(20) betyr hydrogen, alkyl med 1,2, 3,4 eller 5 C-atomer, CvH2v-CF3 eller CwH2w-fenyl, hvor fenylringen er usubstituert eller substituert med 1,2 eller 3 substituenter valgt fra gruppen bestående F, Cl, Br, I, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2, 3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfo- nyl og metylsulfonylamino; v betyr 0,1,2 eller 3; w betyr 0,1,2 eller 3; R(21) betyr hydrogen eller alkyl med 1,2,3,4 eller 5 C-atomer; R(22) betyr alkyl med 1,2,3,4 eller 5 C-atomer; R(4) betyr hydrogen, alkyl med 1,2, 3,4,5 eller 6 C-atomer eller CF3; eller R(3) ogR(4) betyr sammen en kjede på 4 eller 5 metylengrupper, av hvilke en metylengruppe kan være erstattet med -O-, -SO-, -NH-, -N(metyl)- eller -N(benzyl)-; R(5),R(6),R(7)ogR(8) betyr uavhengig av hverandre hydrogen, F, Cl, Br, I, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl eller metylsulfonylamino; R(30)ogR(31) betyr uavhengig av hverandre hydrogen eller alkyl med 1,2 eller 3 C-atomer; eller R(30)ogR(31) betyr sammen en kjede på 2 metylengrupper; så vel som deres farmasøytisk akseptable salter.1. Compounds of formula I, where R(l) means C(0)OR(9), SO2R(10), COR(l 1), C(0)NR(12)R(13) or C(S)NR(12)R(13 ); R(9) means CxH2x-R(14); x means 0,1,2,3 or 4, where x cannot be 0, when R(14) is OR(15) or SO 2 Me; R(14) means alkyl with 1,2, 3,4,5 or 6 C atoms, cycloalkyl with 3,4, 5,6,7,8,9,10 or 11 C atoms, CF3, C2F5, C3F7 , CH2F, CHF2, OR(15), SO2Me, phenyl, naphthyl, biphenylyl, furyl, thienyl or an N-containing heteroaromatic with 1,2, 3,4, 5,6, 7, 8 or 9 C atoms, where phenyl, naphthyl, biphenylyl, furyl, thienyl and the N-containing heteroaromatic are unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH 2 , COMe, NH 2 , OH, alkyl of 1,2,3 or 4 carbon atoms, alkoxy of 1,2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(15) means alkyl with 1,2,3,4 or 5 C atoms, cycloalkyl with 3,4, 5 or 6 C atoms, CF 3 or phenyl, which is unsubstituted or substituted with 1,2 or 3 substituents chosen from the group consisting of F, Cl, Br, I, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1, 2, 3 or 4 C atoms, alkoxy with 1,2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl, and methylsulfonylamino; R(10),R(ll)andR(12) are independently defined as R(9); R(13) means hydrogen, alkyl with 1, 2, 3, or 4 carbon atoms or CF3; R(2) means hydrogen, alkyl with 1,2,3 or 4 carbon atoms or CF3; R(3) means CyH2y-R(16); y means 0,1,2,3 or 4, where y cannot be 0, when R(16) is OR(17) or SO 2 Me; R(16) means alkyl with 1,2, 3,4, 5 or 6 C atoms, cycloalkyl with 3,4, 5,6,7, 8,9,10 or 11 C atoms, CF3, C2F5, C3F7 , CH2F, CHF2, OR(17), SO2Me, phenyl, naphthyl, furyl, thienyl or an N-containing heteroaromatic with 1, 2,3,4,5,6, 7,8 or 9 C atoms, where phenyl, naphthyl, furyl, thienyl and the N-containing heteroaromatic are unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl of 1,2, 3 or 4 C atoms, alkoxy of 1,2,3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(17) means hydrogen, alkyl with 1,2, 3,4 or 5 C atoms, cycloalkyl with 3,4, 5 or 6 C atoms, CF3, phenyl or 2-, 3- or 4-pyridyl, wherein phenyl or 2-, 3- or 4-pyridyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1, 2, 3 or 4 C atoms, alkoxy with 1,2,3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl, and methylsulfonylamino; or R(3) means CHR(18)R(19); R(18) means hydrogen or CzH2z-R(16), where R(16) is defined as above; z means 0, 1, 2 or 3; R(19) means COOH, CONH2, CONR(20)R(21), COOR(22), CH2OH; R(20) means hydrogen, alkyl with 1,2, 3,4 or 5 carbon atoms, CvH2v-CF3 or CwH2w-phenyl, where the phenyl ring is unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1,2, 3 or 4 C atoms, alkoxy with 1,2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfo- nyl and methylsulfonylamino; v means 0, 1, 2 or 3; w means 0, 1, 2 or 3; R(21) means hydrogen or alkyl with 1,2,3,4 or 5 carbon atoms; R(22) means alkyl with 1,2,3,4 or 5 carbon atoms; R(4) means hydrogen, alkyl with 1,2, 3,4,5 or 6 carbon atoms or CF3; or R(3) andR(4) together means a chain of 4 or 5 methylene groups, of which one methylene group may be replaced by -O-, -SO-, -NH-, -N(methyl)- or -N(benzyl)-; R(5),R(6),R(7)andR(8) independently means hydrogen, F, Cl, Br, I, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1,2,3 or 4 C atoms, alkoxy with 1,2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino; R(30)andR(31) means independently hydrogen or alkyl of 1,2 or 3 carbon atoms; or R(30)andR(31) together means a chain of 2 methylene groups; as well as their pharmaceutically acceptable salts. 2. Forbindelser av formel I ifølge krav 1, i hvilke: R(l) betyr C(0)OR(9), SO^IO), COR(l 1) eller C(0)NR(12)R(13); R(9) betyr CxH2x-R(14); x betyr 0,1,2, 3 eller 4, hvor x ikke kan være 0, når R(14) betyr OR(15); R(14) betyr alkyl med 1,2,3,4, 5 eller 6 C-atomer, cykloalkyl med 3,4, 5,6,7, 8 eller 9 C-atomer, CF3, C2F5, OCF3, fenyl, furyl, tienyl eller et N-holdig heteroaromat med 1,2, 3,4, 5, 6, 7, 8 eller 9 C-atomer, hvor fenyl, furyl, tienyl og det N-holdige heteroaromat er usubstituert eller substituert med 1,2 eller 3 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2, 3 eller 4 C-atomer, alkoksy med 1,2,3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(15) betyr alkyl med 1,2,3,4 eller 5 C-atomer, cykloalkyl med 3,4, 5 eller 6 C-atomer, CF3 eller fenyl, som er usubstituert eller substituert med 1,2 eller 3 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, N02, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2,3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(10),R(ll)ogR(12) er uavhengig av hverandre definert som R(9); R(13) betyr hydrogen, alkyl med 1,2,3, eller 4 C-atomer eller CF3; R(2) betyr hydrogen, alkyl med 1, 2, 3 eller 4 C-atomer eller CF3; R(3) betyr CyH2y-R(16); y betyr 0,1,2,3 eller 4, hvor y ikke kan være 0, når R(l6) betyr OR(l 7); R(16) betyr alkyl med 1,2,3 eller 4 C-atomer, cykloalkyl med 3,4, 5,6, 7, 8 eller 9 C-atomer, CF3, C2F5, OR(17), fenyl, furyl, tienyl eller en N-holdig heteroaromat med 1,2,3,4, 5, 6, 7, 8 eller 9 C-atomer, hvor fenyl, furyl, tienyl og det N-holdige heteroaromatet er usubstituert eller substituert med 1,2 eller 3 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(17) betyr alkyl med 1,2,3,4 eller 5 C-atomer, cykloalkyl med 3,4,5 eller 6 C-atomer, CF3, fenyl eller 2-, 3- eller 4-pyridyl, hvor fenyl eller 2-, 3- eller 4-pyridyl er usubstituert eller substituert med 1,2 eller 3 substituenter valgt fra gruppen bestående av F, Cl, Br, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2,3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; eller R(3) betyr CHR(18)R(19); R( 18) betyr hydrogen eller CZH2Z-R( 16), hvor R( 16) er definert som angitt i krav 1; z betyr 0,1,2 eller 3; R(19) betyr CONH2, CONR(20)R(21), COOR(22), CH2OH; R(20) betyr hydrogen, alkyl med 1,2,3,4 eller 5 C-atomer, CvH2v-CF3 eller CwH2w-fenyl, hvor fenylringen er usubstituert eller substituert med 1,2 eller 3 substituenter utvalgt fra gruppen bestående F, Cl, Br, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; v betyr 0,1,2 eller 3; w betyr 0,1,2 eller 3; R(21) betyr hydrogen eller alkyl med 1,2, 3,4 eller 5 C-atomer; R(22) betyr alkyl med 1,2,3,4 eller 5 C-atomer; R(4) betyr hydrogen, alkyl med 1,2, 3,4, 5 eller 6 C-atomer eller CF3; R(5),R(6),R(7)ogR(8) betyr uavhengig av hverandre hydrogen, F, Cl, Br, CF3, NC^, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl eller metylsulfonylamino; R(30)ogR(31) betyr uavhengig av hverandre hydrogen eller alkyl med 1,2 eller 3 C-atomer; eller R(30)ogR(31) betyr sammen en kjede på 2 metylengrupper; så vel som deres farmasøytisk akseptable salter.2. Compounds of formula I according to claim 1, in which: R(1) means C(0)OR(9), SO2IO), COR(11) or C(0)NR(12)R(13); R(9) means CxH2x-R(14); x means 0,1,2,3 or 4, where x cannot be 0, when R(14) means OR(15); R(14) means alkyl with 1,2,3,4, 5 or 6 C atoms, cycloalkyl with 3,4, 5,6,7, 8 or 9 C atoms, CF3, C2F5, OCF3, phenyl, furyl , thienyl or an N-containing heteroaromatic with 1,2, 3,4, 5, 6, 7, 8 or 9 C atoms, where phenyl, furyl, thienyl and the N-containing heteroaromatic are unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl of 1,2, 3 or 4 carbon atoms, alkoxy of 1,2,3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(15) means alkyl with 1,2,3,4 or 5 C atoms, cycloalkyl with 3,4, 5 or 6 C atoms, CF3 or phenyl, which is unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, NO2, CN, COOMe, CONH2, COMe, OH, alkyl with 1,2,3 or 4 C atoms, 1,2,3 or 4 C-atom alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(10),R(ll)andR(12) are independently defined as R(9); R(13) means hydrogen, alkyl with 1,2,3, or 4 carbon atoms or CF3; R(2) means hydrogen, alkyl of 1, 2, 3 or 4 carbon atoms or CF3; R(3) means CyH2y-R(16); y means 0,1,2,3 or 4, where y cannot be 0, when R(l6) means OR(l7); R(16) means alkyl with 1,2,3 or 4 C atoms, cycloalkyl with 3,4, 5,6, 7, 8 or 9 C atoms, CF3, C2F5, OR(17), phenyl, furyl, thienyl or an N-containing heteroaromatic with 1,2,3,4, 5, 6, 7, 8 or 9 C atoms, wherein phenyl, furyl, thienyl and the N-containing heteroaromatic are unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl of 1,2,3 or 4 C atoms, alkoxy of 1,2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(17) means alkyl with 1,2,3,4 or 5 C atoms, cycloalkyl with 3,4,5 or 6 C atoms, CF3, phenyl or 2-, 3- or 4-pyridyl, wherein phenyl or 2-, 3- or 4-pyridyl is unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, OH, alkyl of 1,2,3 or 4 C atoms, alkoxy of 1,2,3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; or R(3) means CHR(18)R(19); R( 18 ) means hydrogen or CZH2Z-R( 16 ), where R( 16 ) is defined as given in claim 1; z means 0, 1, 2 or 3; R(19) means CONH2, CONR(20)R(21), COOR(22), CH2OH; R(20) means hydrogen, alkyl with 1,2,3,4 or 5 carbon atoms, CvH2v-CF3 or CwH2w-phenyl, where the phenyl ring is unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1,2,3 or 4 C-atoms, 1,2, 3 or 4 C-atom alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; v means 0, 1, 2 or 3; w means 0, 1, 2 or 3; R(21) means hydrogen or alkyl with 1,2, 3,4 or 5 carbon atoms; R(22) means alkyl with 1,2,3,4 or 5 carbon atoms; R(4) means hydrogen, alkyl of 1,2, 3,4, 5 or 6 carbon atoms or CF3; R(5),R(6),R(7)andR(8) independently means hydrogen, F, Cl, Br, CF3, NC^, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1,2,3 or 4 C atoms, alkoxy with 1,2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino; R(30)andR(31) means independently hydrogen or alkyl of 1,2 or 3 carbon atoms; or R(30)andR(31) together means a chain of 2 methylene groups; as well as their pharmaceutically acceptable salts. 3. Forbindelser av formel I ifølge krav 1 eller 2, i hvilke: R(l) betyr C(0)OR(9), SO^IO), COR(l 1) eller C(0)NR(12)R(13); R(9) erCxH2x-R(14); x betyr 0,1,2, 3 eller 4, hvor x ikke kan være 0, når R(14) betyr OR(15) eller S02Me; R(14) betyr cykloalkyl med 3,4,5,6, 7, 8 eller 9 C-atomer, CF3, OR(15), fenyl, furyl, tienyl eller et N-holdig heteroaromat med 3,4 eller 5 C-atomer, hvor fenyl, furyl, tienyl og det N-holdige heteroaromat er usubstituert eller substituert med 1 eller 2 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsmfon<y>larnino; R(15) betyr alkyl med 1 eller 2 C-atomer, cykloalkyl med 3,4,5 eller 6 C-atomer, CF3 eller fenyl, som er usubstituert eller substituert med 1 eller 2 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(10),R(ll)ogR(12) er uavhengig av hverandre definert som R(9); R(13) betyr hydrogen; R(2) betyr hydrogen eller alkyl med 1,2 eller 3 C-atomer; R(3) betyrCHR(18)R(19); R(l8) betyr hydrogen eller CzH2z-R(l6); z betyr 0,1,2 eller 3; R(19) betyr CONH2, CONR(20)R(21), COOR(22) eller CH2OH; R(20) betyr hydrogen, alkyl med 1,2,3,4 eller 5 C-atomer, CvH2v-CF3 eller CwH2w-fenyl, hvor fenylringen er usubstituert eller substituert med 1,2 eller 3 substituenter utvalgt fra gruppen bestående F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; v betyr 0,1,2 eller 3; w betyr 0,1,2 eller 3; R(21) betyr hydrogen eller alkyl med 1,2,3,4 eller 5 C-atomer; R(22) betyr alkyl med 1,2, 3,4 eller 5 C-atomer; R(16) betyr alkyl med 1,2 eller 3 C-atomer, cykloalkyl med 3,4, 5,6, 7, 8 eller 9 C-atomer, CF3, OR(17), fenyl, furyl, tienyl eller en N-holdig heteroaromat med 3,4 eller 5 C-atomer, hvor fenyl, furyl, tienyl og det N-holdige heteromatet er usubstituert eller substituert med 1 eller 2 valgt blant gruppen bestående av F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1, 2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(17) betyr alkyl med 1,2,3,4 eller 5 C-atomer, cykloalkyl med 3,4, 5 eller 6 C-atomer, CF3, fenyl eller 2-, 3- eller 4-pyridyl, hvor fenyl eller 2-, 3- eller 4-pyridyl er usubstituert eller substituert med 1,2 eller 3 substituenter valgt fra gruppen bestående av F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2,3 eller 4 C-atomer, alkoksy med 1,2,3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(4) betyr hydrogen eller alkyl med 1 eller 2 C-atomer; R(5),R(6),R(7)ogR(8) betyr uavhengig av hverandre hydrogen, F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl eller metylsulfonylamino; R(30)ogR(31) betyr uavhengig av hverandre hydrogen eller metyl; eller R(30)ogR(31) betyr sammen en kjede på 2 metylengrupper; så vel som deres farmasøytisk akseptable salter.3. Compounds of formula I according to claim 1 or 2, in which: R(l) means C(0)OR(9), SO^IO), COR(l 1) or C(0)NR(12)R(13) ; R(9) is CxH2x-R(14); x means 0,1,2,3 or 4, where x cannot be 0, when R(14) is OR(15) or SO 2 Me; R(14) means cycloalkyl with 3,4,5,6, 7, 8 or 9 C atoms, CF3, OR(15), phenyl, furyl, thienyl or an N-containing heteroaromatic with 3,4 or 5 C atoms, where phenyl, furyl, thienyl and the N-containing heteroaromatic are unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl with 1, 2 or 3 C atoms, 1 or 2 C alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsmfon<y>larnino; R(15) means alkyl with 1 or 2 C atoms, cycloalkyl with 3,4,5 or 6 C atoms, CF3 or phenyl, which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, OH, alkyl of 1,2 or 3 carbon atoms, alkoxy of 1 or 2 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(10),R(ll)andR(12) are independently defined as R(9); R(13) means hydrogen; R(2) means hydrogen or alkyl of 1,2 or 3 carbon atoms; R(3) means CHR(18)R(19); R(18) means hydrogen or CzH2z-R(16); z means 0, 1, 2 or 3; R(19) is CONH2, CONR(20)R(21), COOR(22) or CH2OH; R(20) means hydrogen, alkyl with 1,2,3,4 or 5 carbon atoms, CvH2v-CF3 or CwH2w-phenyl, where the phenyl ring is unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl with 1,2 or 3 C atoms, alkoxy with 1 or 2 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; v means 0, 1, 2 or 3; w means 0, 1, 2 or 3; R(21) means hydrogen or alkyl with 1,2,3,4 or 5 carbon atoms; R(22) means alkyl with 1,2, 3,4 or 5 carbon atoms; R(16) means alkyl with 1,2 or 3 C atoms, cycloalkyl with 3,4, 5,6, 7, 8 or 9 C atoms, CF3, OR(17), phenyl, furyl, thienyl or an N -containing heteroaromatic with 3,4 or 5 C atoms, where phenyl, furyl, thienyl and the N-containing heteromate are unsubstituted or substituted with 1 or 2 selected from the group consisting of F, Cl, Br, CF3, OCF3, CN, COOMe, CONH 2 , COMe, NH 2 , OH, alkyl of 1, 2 or 3 C atoms, alkoxy of 1 or 2 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(17) means alkyl with 1,2,3,4 or 5 C atoms, cycloalkyl with 3,4, 5 or 6 C atoms, CF3, phenyl or 2-, 3- or 4-pyridyl, wherein phenyl or 2-, 3- or 4-pyridyl is unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl with 1,2,3 or 4 C atoms, 1,2,3 or 4 C alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(4) means hydrogen or alkyl with 1 or 2 carbon atoms; R(5),R(6),R(7)andR(8) independently means hydrogen, F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1,2 or 3 C atoms, alkoxy with 1 or 2 C atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino; R(30)andR(31) means independently hydrogen or methyl; or R(30)andR(31) together means a chain of 2 methylene groups; as well as their pharmaceutically acceptable salts. 4. Forbindelser av formel I ifølge krav 1 eller 2, i hvilke: R(l) betyr C(0)OR(9), SO2R(10), COR(l 1) eller C(0)NR(12)R(13); R(9) erCxH2x-R(14); x betyr 0,1,2,3 eller 4, hvor x ikke kan være 0, når R(14) betyr OR(l 5); R(14) betyr alkyl med 1,2,3 eller 4 C-atomer, cykloalkyl med 3,4, 5,6, 7, 8 eller 9 C-atomer, CF3, OR(15), fenyl, furyl, tienyl eller et N-holdig heteroaromat med 3,4 eller 5 C-atomer, hvor fenyl, furyl, tienyl og det N-holdige heteroaromat er usubstituert eller substituert med 1 eller 2 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(15) betyr alkyl med 1 eller 2 C-atomer, cykloalkyl med 3,4, 5 eller 6 C-atomer, CF3 eller fenyl, som er usubstituert eller substituert med 1 eller 2 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(10),R(ll)ogR(12) er uavhengig av hverandre definert som R(9); R(13) betyr hydrogen; R(2) betyr hydrogen eller alkyl med 1,2 eller 3 C-atomer; R(3) betyr CyH2y-R(16); y betyr 0,1,2,3 eller 4, hvor y ikke kan være 0, når R(16) betyr OR(17); R(16) betyr alkyl med 1,2 eller 3 C-atomer, cykloalkyl med 3,4, 5,6, 7, 8 eller 9 C-atomer, CF3, OR(17), fenyl, furyl, tienyl eller en N-holdig heteroaromat med 3,4 eller 5 C-atomer, hvor fenyl, furyl, tienyl og det N-holdige heteroaromatet er usubstituert eller substituert med 1 eller 2 substituenter valgt blant gruppen bestående av F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(17) betyr alkyl med 1,2, 3,4 eller 5 C-atomer, cykloalkyl med 3,4, 5 eller 6 C-atomer, CF3, fenyl eller 2-, 3- eller 4-pyridyl, hvor fenyl eller 2-, 3- eller 4-pyridyl er usubstituert eller substituert med 1,2 eller 3 substituenter valgt fra gruppen bestående av F, Cl, Br, CF3, OCF3, N02, CN, COOMe, CONH2, COMe, OH, alkyl med 1,2, 3 eller 4 C-atomer, alkoksy med 1,2, 3 eller 4 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl og metylsulfonylamino; R(4) betyr hydrogen eller alkyl med 1 eller 2 C-atomer; R(5),R(6),R(7)ogR(8) betyr uavhengig av hverandre hydrogen, F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, NH2, OH, alkyl med 1,2 eller 3 C-atomer, alkoksy med 1 eller 2 C-atomer, dimetylamino, sulfamoyl, metylsulfonyl eller metylsulfonylamino; R(30)ogR(31) betyr uavhengig av hverandre hydrogen eller metyl; eller R(30)ogR(31) betyr sammen en kjede på 2 metylengrupper; så vel som deres farmasøytisk akseptable salter.4. Compounds of formula I according to claim 1 or 2, in which: R(l) means C(0)OR(9), SO2R(10), COR(l 1) or C(0)NR(12)R(13) ; R(9) is CxH2x-R(14); x means 0,1,2,3 or 4, where x cannot be 0, when R(14) means OR(15); R(14) means alkyl with 1,2,3 or 4 C atoms, cycloalkyl with 3,4, 5,6, 7, 8 or 9 C atoms, CF3, OR(15), phenyl, furyl, thienyl or an N-containing heteroaromatic with 3,4 or 5 C atoms, where phenyl, furyl, thienyl and the N-containing heteroaromatic are unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, OH, alkyl with 1, 2 or 3 C atoms, 1 or 2 C alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(15) means alkyl with 1 or 2 C atoms, cycloalkyl with 3,4, 5 or 6 C atoms, CF3 or phenyl, which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, OH, alkyl with 1,2 or 3 C atoms, alkoxy with 1 or 2 C -atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(10),R(ll)andR(12) are independently defined as R(9); R(13) means hydrogen; R(2) means hydrogen or alkyl of 1,2 or 3 carbon atoms; R(3) means CyH2y-R(16); y means 0,1,2,3 or 4, where y cannot be 0, when R(16) means OR(17); R(16) means alkyl with 1,2 or 3 C atoms, cycloalkyl with 3,4, 5,6, 7, 8 or 9 C atoms, CF3, OR(17), phenyl, furyl, thienyl or an N -containing heteroaromatic with 3,4 or 5 C atoms, where phenyl, furyl, thienyl and the N-containing heteroaromatic are unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1,2 or 3 carbon atoms, 1 or 2 carbon atom alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(17) means alkyl with 1,2, 3,4 or 5 C atoms, cycloalkyl with 3,4, 5 or 6 C atoms, CF3, phenyl or 2-, 3- or 4-pyridyl, wherein phenyl or 2-, 3- or 4-pyridyl is unsubstituted or substituted with 1,2 or 3 substituents selected from the group consisting of F, Cl, Br, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, OH, alkyl of 1,2, 3 or 4 C atoms, alkoxy of 1,2, 3 or 4 C atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R(4) means hydrogen or alkyl with 1 or 2 carbon atoms; R(5),R(6),R(7)andR(8) independently means hydrogen, F, Cl, Br, CF3, CN, COOMe, CONH2, COMe, NH2, OH, alkyl with 1,2 or 3 C atoms, alkoxy with 1 or 2 C atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino; R(30)andR(31) means independently hydrogen or methyl; or R(30)andR(31) together means a chain of 2 methylene groups; as well as their pharmaceutically acceptable salts. 5. Forbindelser av formel I ifølge et eller flere av kravene 1,2 eller 4, hvor: R(l) betyr C(0)OR(9), SO^IO), COR(l 1) eller C(0)NR(12)R(13); R(9) erCxHzx-RCH); x betyr 0,1,2 eller 3, R(14) betyr alkyl med 1,2,3 eller 4 C-atomer, cykloalkyl med 3,4, 5,6, 7, 8 eller 9 C-atomer, CF3, fenyl eller pyridyl, hvor fenyl og pyridyl er usubstituert eller substituert med 1 eller 2 substituenter valgt blant gruppen bestående av F, Cl, CF3, OCF3, alkyl med 1,2 eller 3 C-atomer og alkoksy med 1 eller 2 C-atomer; R(10),R(ll)ogR(12) er uavhengig av hverandre definert som R(9); R(13) betyr hydrogen; R(2) betyr hydrogen; R(3) betyr CyH2y-R(16); y betyr 0,1 eller 2, R(16) betyr alkyl med 1,2 eller 3 C-atomer, cykloalkyl med 5 eller 6 C- atomer, CF3, fenyl eller pyridyl, hvor fenyl og pyridyl er usubstituert eller substituert med 1 eller 2 substituenter uvalgt fra gruppen bestående av F, Cl, CF3, OCF3, OH, alkyl med 1,2 eller 3 C-atomer og alkoksy med 1 eller 2 C-atomer; R(4) betyr hydrogen; R(5),R(6),R(7)ogR(8) betyr uavhengig av hverandre hydrogen, F, CF3, CN, COOMe, NH2, OH, alkyl med 1,2 eller 3 C-atomer eller alkoksy med 1 eller 2 C-atomer; R(30)ogR(31) betyr uavhengig av hverandre hydrogen eller metyl; eller R(30)ogR(31) betyr sammen en kjede på 2 metylengrupper; så vel som deres farmasøytisk akseptable salter.5. Compounds of formula I according to one or more of claims 1, 2 or 4, where: R(l) means C(0)OR(9), SO^IO), COR(l 1) or C(0)NR(12 )R(13); R(9) is CxHzx-RCH); x means 0,1,2 or 3, R(14) means alkyl with 1,2,3 or 4 C atoms, cycloalkyl with 3,4, 5,6, 7, 8 or 9 C atoms, CF3, phenyl or pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, CF 3 , OCF 3 , alkyl with 1,2 or 3 C atoms and alkoxy with 1 or 2 C atoms; R(10),R(ll)andR(12) are independently defined as R(9); R(13) means hydrogen; R(2) means hydrogen; R(3) means CyH2y-R(16); y means 0,1 or 2, R(16) means alkyl with 1,2 or 3 C atoms, cycloalkyl with 5 or 6 C- atoms, CF3, phenyl or pyridyl, where phenyl and pyridyl are unsubstituted or substituted with 1 or 2 substituents unselected from the group consisting of F, Cl, CF3, OCF3, OH, alkyl with 1,2 or 3 C atoms and alkoxy with 1 or 2 C atoms; R(4) means hydrogen; R(5),R(6),R(7)andR(8) means independently hydrogen, F, CF 3 , CN, COOMe, NH 2 , OH, alkyl of 1,2 or 3 C atoms or alkoxy of 1 or 2 C atoms; R(30)andR(31) means independently hydrogen or methyl; or R(30)andR(31) together means a chain of 2 methylene groups; as well as their pharmaceutically acceptable salts. 6. Forbindelser av formel I ifølge et eller flere av kravene 1,2 eller 4, hvor: R(l) betyr C(0)OR(9) eller COR(l 1); R(9) erC,H2x-R(14); x betyr 0,1,2 eller 3, R(14) betyr alkyl med 5 eller 6 C-atomer eller fenyl, hvor fenyl er usubstituert eller substituert med 1 eller 2 substituenter valgt fra gruppen bestående av F, Cl, CF3, OCF3, alkyl med 1,2 eller 3 C-atomer og alkoksy med 1 eller 2 C-atomer; R(ll) er definert som R(9); R(2) betyr hydrogen; R(3) betyrCyH2y-R(16); y betyr 0,1 eller 2, R(16) betyr alkyl med 1,2 eller 3 C-atomer, cykloalkyl med 5 eller 6 C- atomer, CF3, fenyl eller pyridyl, hvor fenyl og pyridyl er usubstituert eller substituert med 1 eller 2 substituenter uvalgt fra gruppen bestående av F, Cl, CF3, OCF3, alkyl med 1,2 eller 3 C-atomer og alkoksy med 1 eller 2 C-atomer; R(4) betyr hydrogen; R(5),R(6),R(7)ogR(8) betyr uavhengig av hverandre hydrogen, F, CF3, alkyl med 1,2 eller 3 C-atomer eller alkoksy med 1 eller 2 C-atomer; R(30)ogR(31) betyr hydrogen; så vel som deres farmasøytisk: akseptable salter.6. Compounds of formula I according to one or more of claims 1, 2 or 4, where: R(l) means C(0)OR(9) or COR(l 1); R(9) is C,H 2 x -R(14); x means 0,1,2 or 3, R(14) means alkyl with 5 or 6 carbon atoms or phenyl, wherein phenyl is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, CF 3 , OCF 3 , alkyl with 1, 2 or 3 C atoms and alkoxy with 1 or 2 C atoms; R(II) is defined as R(9); R(2) means hydrogen; R(3) means CyH2y-R(16); y means 0,1 or 2, R(16) means alkyl with 1,2 or 3 C atoms, cycloalkyl with 5 or 6 C- atoms, CF3, phenyl or pyridyl, where phenyl and pyridyl are unsubstituted or substituted with 1 or 2 substituents unselected from the group consisting of F, Cl, CF3, OCF3, alkyl with 1,2 or 3 C atoms and alkoxy with 1 or 2 C atoms; R(4) means hydrogen; R(5),R(6),R(7)andR(8) independently means hydrogen, F, CF 3 , alkyl of 1,2 or 3 C atoms or alkoxy of 1 or 2 C atoms; R(30)andR(31) means hydrogen; as well as their pharmaceutically:acceptable salts. 7. Forbindelse av formel I ifølge et eller flere av kravene 1,2,4, S eller 6 som er så vel som dens farmasøytisk akseptable salter.7. Compound of formula I according to one or more of claims 1, 2, 4, S or 6 which is as well as its pharmaceutically acceptable salts. 8. Forbindelser av formel I ifølge et eller flere av kravene 1 til 7 og deres farmasøytisk akseptable salter for anvendelse som legemiddel.8. Compounds of formula I according to one or more of claims 1 to 7 and their pharmaceutically acceptable salts for use as medicine. 9. Farmasøytisk preparat inneholdende en effektiv mengde av minst en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav som virkestoff, sammen med farmasøytisk akseptable bære- og tilsetningsstoffer og eventuelt også et eller flere andre farmakologiske virkestoffer.9. Pharmaceutical preparation containing an effective amount of at least one compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof as active ingredient, together with pharmaceutically acceptable carriers and additives and optionally also one or more other pharmacological active ingredients . 10. Anvendelse av en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament med K<+->kanalblokkerende virkning for terapi eller profylakse av K<+->kanalmedierte sykdommer.10. Use of a compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof for the preparation of a drug with K<+-> channel-blocking action for therapy or prophylaxis of K<+-> channel-mediated diseases. 11. Anvendelse av en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt herav for fremstilling av et medikament for terapi eller profylakse av hjerterytmeforstyrrelser, som kan oppheves ved forskyvning av aksjonspotensialet.11. Use of a compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof for the preparation of a drug for the therapy or prophylaxis of heart rhythm disturbances, which can be reversed by shifting the action potential. 12. Anvendelse av en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for terapi eller profylakse av Reentry-arrytmier.12. Use of a compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the therapy or prophylaxis of reentry arrhythmias. 13. Anvendelse av en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for terapi eller profylakse av supraventrikulære arrytmier.13. Use of a compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the therapy or prophylaxis of supraventricular arrhythmias. 14. Anvendelse av en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for terapi eller profylakse av atriell fibrillasjon eller atriell flapring.14. Use of a compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the therapy or prophylaxis of atrial fibrillation or atrial flutter. 15. Anvendelse av en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for terminering av arteriell fibrillasjon eller arteriell flapring (kardioversjon).15. Use of a compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the termination of arterial fibrillation or arterial flapping (cardioversion). 16. Farmasøytisk preparat inneholdende en effektiv mengde av minst en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav så vel som en IKr-kanalblokker som virkestoff sammen med farmasøytisk akseptable bære- og tilsetningsstoffer.16. Pharmaceutical preparation containing an effective amount of at least one compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof as well as an IKr channel blocker as active ingredient together with pharmaceutically acceptable carriers and additives. 17. Farmasøytisk preparat inneholdende en effektiv mengde av minst en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav så vel som en IKs-kanalblokker som virkestoff sammen med farmasøytisk akseptable bære- og tilsetningsstoffer.17. Pharmaceutical preparation containing an effective amount of at least one compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof as well as an IKs channel blocker as active ingredient together with pharmaceutically acceptable carriers and additives. 18. Farmasøytisk preparat inneholdende en effektiv mengde av minst en forbindelse av formel I ifølge et eller flere av kravene 1 til 7 og/eller et farmasøytisk akseptabelt salt derav så vel som en betablokker som virkestoff sammen med farmasøytisk anvendelige bære- og tilsetningsstoffer.18. Pharmaceutical preparation containing an effective amount of at least one compound of formula I according to one or more of claims 1 to 7 and/or a pharmaceutically acceptable salt thereof as well as a beta blocker as active ingredient together with pharmaceutically usable carriers and additives.
NO20021398A 1999-10-02 2002-03-20 2'-substituted 1,1'-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them NO327709B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947457A DE19947457A1 (en) 1999-10-02 1999-10-02 New 2'-aminomethyl-biphenyl-2-carboxamide derivatives, are potassium channel blockers especially useful for treating re-entry or supraventricular arrhythmia or atrial fibrillation or flutter
PCT/EP2000/009151 WO2001025189A1 (en) 1999-10-02 2000-09-19 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds

Publications (3)

Publication Number Publication Date
NO20021398D0 NO20021398D0 (en) 2002-03-20
NO20021398L NO20021398L (en) 2002-05-31
NO327709B1 true NO327709B1 (en) 2009-09-14

Family

ID=7924254

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021398A NO327709B1 (en) 1999-10-02 2002-03-20 2'-substituted 1,1'-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them

Country Status (32)

Country Link
EP (1) EP1222163B1 (en)
JP (1) JP4713800B2 (en)
KR (1) KR100722178B1 (en)
CN (1) CN1195738C (en)
AR (1) AR031226A1 (en)
AT (1) ATE332890T1 (en)
AU (1) AU766365B2 (en)
BR (1) BR0014465B1 (en)
CA (1) CA2385859C (en)
CY (1) CY1106178T1 (en)
CZ (1) CZ302591B6 (en)
DE (2) DE19947457A1 (en)
DK (1) DK1222163T3 (en)
EE (1) EE05000B1 (en)
ES (1) ES2265985T3 (en)
HK (1) HK1048986B (en)
HR (1) HRP20020264B1 (en)
HU (1) HU229046B1 (en)
IL (2) IL148870A0 (en)
ME (1) MEP60908A (en)
MX (1) MXPA02002691A (en)
NO (1) NO327709B1 (en)
NZ (1) NZ518065A (en)
PL (1) PL204034B1 (en)
PT (1) PT1222163E (en)
RS (1) RS50387B (en)
RU (1) RU2252214C2 (en)
SK (1) SK286756B6 (en)
TR (1) TR200200883T2 (en)
TW (1) TWI270541B (en)
WO (1) WO2001025189A1 (en)
ZA (1) ZA200202521B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266346A1 (en) 2000-06-28 2002-01-08 Takeda Chemical Industries Ltd. Biphenyl compound
DE10059418A1 (en) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
DE10060807A1 (en) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
DE10121003A1 (en) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
JPWO2002098840A1 (en) 2001-06-04 2004-09-16 エーザイ株式会社 Pharmaceuticals comprising carboxylic acid derivatives and their salts or esters
DE10128331A1 (en) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh New 2-(heteroarylsulfonyl-amino)-benzamide derivatives, which are potassium ion channel blocking antiarrhythmic agents, useful for e.g. treating atrial fibrillation or flutter
US7507753B2 (en) 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
JP4690889B2 (en) * 2002-10-24 2011-06-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Methylene urea derivative
DE10312061A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Combination of phenylcarboxamides with blockers of the IK channel and their use for the treatment of atrial arrhythmias
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
DE10341233A1 (en) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Composition, useful to treat e.g. atrial fibrillation, atrial flutter and atrial arrhythmia, comprises at least one beta-blocker and at least one compound of a phenylcarboxylic acid amide derivative
DE102004009931A1 (en) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Use of specific 2-substituted benzamides for treating and preventing cardiac insufficiency, especially where caused by diastolic dysfunction, act by inhibition of the Kv1.5 potassium channel
JP2007528420A (en) * 2004-03-11 2007-10-11 グラクソ グループ リミテッド Novel M3 muscarinic acetylcholine receptor antagonist
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
BRPI0710946A2 (en) * 2006-04-27 2012-03-06 Sanofi-Aventis Deutschland Gmbh Ion channel inhibitors task-1 and task-3
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
SG175703A1 (en) * 2009-06-03 2011-12-29 Sanofi Aventis Deutschland Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (en) 2011-07-01 2018-04-28
CA2862670A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (en) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K BIPHENYL DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHOD FOR THE PRODUCTION THEREOF
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
AU766365B2 (en) 2003-10-16
TWI270541B (en) 2007-01-11
PL354322A1 (en) 2004-01-12
TR200200883T2 (en) 2002-09-23
SK286756B6 (en) 2009-05-07
HRP20020264B1 (en) 2010-08-31
CN1195738C (en) 2005-04-06
ATE332890T1 (en) 2006-08-15
AU7777800A (en) 2001-05-10
CY1106178T1 (en) 2011-06-08
RU2252214C2 (en) 2005-05-20
HUP0203505A3 (en) 2004-01-28
KR20020038791A (en) 2002-05-23
RU2002111561A (en) 2004-01-20
PL204034B1 (en) 2009-12-31
NZ518065A (en) 2004-08-27
DE19947457A1 (en) 2001-04-05
KR100722178B1 (en) 2007-05-29
EE05000B1 (en) 2008-04-15
CZ302591B6 (en) 2011-07-27
HU229046B1 (en) 2013-07-29
PT1222163E (en) 2006-10-31
ES2265985T3 (en) 2007-03-01
MEP60908A (en) 2011-05-10
DE50013167D1 (en) 2006-08-24
SK4382002A3 (en) 2002-08-06
NO20021398D0 (en) 2002-03-20
ZA200202521B (en) 2002-12-24
EP1222163A1 (en) 2002-07-17
RS50387B (en) 2009-12-31
AR031226A1 (en) 2003-09-17
BR0014465B1 (en) 2011-12-27
NO20021398L (en) 2002-05-31
MXPA02002691A (en) 2002-07-30
JP2003511363A (en) 2003-03-25
HRP20020264A2 (en) 2004-02-29
EE200200160A (en) 2003-04-15
DK1222163T3 (en) 2006-11-13
WO2001025189A1 (en) 2001-04-12
CA2385859C (en) 2009-11-24
BR0014465A (en) 2002-06-11
IL148870A (en) 2007-05-15
HK1048986A1 (en) 2003-04-25
CZ20021144A3 (en) 2002-06-12
HK1048986B (en) 2005-07-29
HUP0203505A2 (en) 2003-03-28
CA2385859A1 (en) 2001-04-12
CN1373750A (en) 2002-10-09
IL148870A0 (en) 2002-09-12
YU24402A (en) 2005-06-10
EP1222163B1 (en) 2006-07-12
JP4713800B2 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
NO327709B1 (en) 2&#39;-substituted 1,1&#39;-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them
CA2430273A1 (en) Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them
RU2003119153A (en) ORTHO-, META-SUBSTITUTED BIS-Aryl COMPOUNDS, METHOD FOR PRODUCING THEM, THEIR APPLICATION AS MEDICINES, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
RU2003121236A (en) AILATED AMIDES OF FURAN- AND THIOPHENCARBOXYLIC ACIDS WITH LOCKING POTASSIUM CHANNEL ACTION
RU2003120080A (en) ORTHO-SUBSTITUTED NITROGEN-CONTAINING BISARYL COMPOUNDS FOR APPLICATION AS POTASSIUM CHANNEL INHIBITORS, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
CA2445341A1 (en) Anthranilamides, process for their preparation, their use as antiarrhythmics, and pharmaceutical preparations thereof
RU2309946C2 (en) New compounds as anti-inflammatory, immunomodulating, and anti-proliferative agents
RU2328486C2 (en) 2-pyridone derivatives as inhibitors of neutrophil elastase
CA2450076A1 (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or a diagnostic agent and pharmaceutical preparations containing said compounds
JP2004515493A5 (en)
ZA200303931B (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors.
RU94019971A (en) 1,3-DIGIDRO-2N-IMIDAZO / 4,5-V / QUINOLIN-2-SHE DERIVATIVES AS AN INHIBITORS, PHOSPHODESTERRASES, METHOD OF THEIR RECEIVING, INTERMEDIATE FOR THEM, PHARMACEUTICAL COMPOSITION CHAPTER.
DK1119567T3 (en) quinazoline
NO20061657L (en) Pyrol derivatives with antibacterial activity
NZ515282A (en) Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions
RU99104152A (en) CYCLIC AMINUM DERIVATIVES
PT81814B (en) PROCESS FOR THE PREPARATION OF NAFETHALINE DERIVATIVES
CA2626767A1 (en) Heterocyclic substituted pyridine derivatives and antifungal agent containing same
EP3786156B1 (en) 10h-phenothiazine ferroptosis inhibitor and preparation method therefor and application thereof
UA72945C2 (en) A compound (variants), a pharmaceutical composition, a method for treatment (variants)
NO20051901L (en) New antimycobacterial compositions and pyrrole derivatives such as antimycobacterial compositions
CA2523196A1 (en) Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
RU2001126566A (en) Pyrazol-3-one derivatives
RU2001124813A (en) Aminomethylpyrrolidine derivatives having aromatic substituents
RU98117567A (en) SULFONAMID SUBSTITUTED CHROMANAS, METHODS FOR PRODUCING THEM, THEIR USE AS MEDICINES, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees